[Closed] EUnetHTA 21 launches Open Call for JSC
EUnetHTA 21 is launching the first Open Call for applications from the pharmaceutical industry for four Joint Scientific Consultations (JSC), starting in January 2022. These will be consultations in parallel to EMA scientific advice and hence will focus on medicinal products. The Open Call will remain open from 8 November, 2021 to 7 December, 2021. […]
EUnetHTA 21 JSC – open calls
As one of the first milestones of EUnetHTA 21, we will soon launch the first open call to pharmaceutical industry for applications for the upcoming Joint Scientific Consultations, starting in January 2022. These will be consultations in parallel to EMA scientific advice and hence will focus on medicinal products. The launch of the open call […]
European HTA agencies launch the Heads of Agencies Group (HAG)
On 29 September 2021, the heads of 19 European HTA agencies came together and inaugurated a new HTA-focused collaborative network for high-level strategic exchange and discussion. In the coming period, the Heads of Agencies Group will focus on: Supporting the development of the basis for joint work on all HTA activities at the EU level […]
EUnetHTA 21
On 17 September 2021, the European Health and Digital Executive Agency (HaDEA) signed the Service Contract for the Provision of Joint Health Technology Assessment (HTA) Work Supporting the Continuation of EU Cooperation on HTA. The contract will run for 24 months, and until 16 September 2023. EUnetHTA 21 work will build on the achievements and lessons […]
Future Model of Cooperation (FMC) – White Paper
EUnetHTA has become synonymous with HTA in Europe, a trademark, in fact, that stands for a community of professionals dedicated to continuously improve the standards and quality of their own work, to ultimately achieve ever better results for patients. This dedication of more than 15 years has lead to the creation of a European legal […]
OTCA26 Obesity Surgery Project – Final Assessment now available
The final report is now available for the Relative Effectiveness Assessment OTCA26 “Surgical procedures for treatment of obesity”. The aim of this multi-technology HTA was to assess the comparative effectiveness (and possible superiority) and safety of different surgical treatments for adult patients with obesity (AGB, SG, RYGB, D-RYGB, OAGB, BPD-DS, BPD,SASI, SADI-S). Only data from […]
EUnetHTA Magazine Summer 2021 – now available
We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to publish on a quarterly basis, the changes we have all experienced over the past year and a half have, understandably, presented a challenge to generating articles while our ‘regular’ workflows […]
PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. In June, 2021, the European Commission granted marketing authorisation for Venclyxto® (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid […]
EUnetHTA and EMA take stock of their cooperation
The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017. The report covers the latest phase of an open and successful collaboration that began in 2010, and demonstrated that the synergies between regulatory evaluation and health technology assessment (HTA) along […]
OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- final report now available
The final report is now available for the Relative Effectiveness Assessment OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)”. The aim of this multi-technology HTA was to assess 21 minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), either comparing minimally invasive treatments to each other or […]
